🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase III

Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
1,266

Quick answer

Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 7 of 27

  1. DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN

    Fondazione Telethon ETS

    Favorable-intermediate-risk Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. DCC-3014, DCC-3014, Placebo to match DCC-3014

    Lacuna Pharma Pty Ltd

    Tenosynovial Giant Cell Tumor

    phase 3 small molecule active

    1 trial

  3. DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN

    Ningbo Cancer Hospital

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  4. DEXAMETHASONE , FLUDARABINE , CISPLATIN , OXALIPLATIN , CARBOPLATIN , LENALIDOMIDE , RITUXIMAB , TOCILIZUMAB , CYCLOPHOSPHAMIDE , BENDAMUSTINE , TISAGENLECLEUCEL, IFOSFAMIDE , MELPHALAN , CYTARABINE , CARMUSTINE , IBRUTINIB , ETOPOSIDE , GEMCITABINE

    Novartis Pharmaceuticals

    Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

    phase 3 small molecule active

    1 trial

  5. DEXAMETHASONE , MK-2870, -, -, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  6. DEXAMETHASONE, CAPECITABINE , OXALIPLATIN , FLUOROURACIL , FOLINIC ACID, METOCLOPRAMIDE, ONDANSETRON

    The George Institute

    locally advanced rectal cancer

    phase 3 small molecule active

    1 trial

  7. DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE

    Pari Pharma GmbH

    Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

    phase 3 small molecule active

    1 trial

  8. DEXAMETHASONE, RITUXIMAB, BLINATUMOMAB, MERCAPTOPURINE, RITUXIMAB, BLINATUMOMAB, CYCLOPHOSPHAMIDE, PREDNISONE, CYTARABINE, IDARUBICIN, PREDNISOLONE, METHOTREXATE SODIUM, DEXAMETHASONE, DEXAMETHASONE, CYCLOPHOSPHAMIDE, PEGASPARGASE, DOXORUBICIN, CYTARABINE, DEXAMETHASONE, MERCAPTOPURINE, VINCRISTINE SULFATE, METHOTREXATE SODIUM, METHOTREXATE SODIUM, VINCRISTINE SULFATE, ASPARAGINASE, CRISANTASPASE, METHOTREXATE SODIUM

    Amgen

    Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults

    phase 3 small molecule active

    1 trial

  9. DEXAMETHASONE, Xtandi - 40 mg soft capsules, PF-06821497, DEXAMETHASONE, PF-06821497, PREDNISOLONE, DOCETAXEL

    Pfizer Australia Pty Ltd

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  10. DOCETAXEL

    Pfizer Australia Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  11. DOCETAXEL , MK-2870, VINFLUNINE , PACLITAXEL , MK-2870, -, -

    Merck Sharp and Dohme

    Locally advanced/metastatic urothelial carcinoma

    phase 3 small molecule active

    1 trial

  12. DOCETAXEL, Inflectra 100 mg powder for concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, DOCETAXEL, INFLIXIMAB, Remsima 100 mg powder for concentrate for solution for infusion, Ceralasertib, MYCOPHENOLATE MOFETIL, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, DOCETAXEL, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL

    Genmab A/S

    Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer

    phase 3 small molecule active

    1 trial

  14. DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, PACLITAXEL, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, TOPOTECAN, AZD5335, MIRVETUXIMAB SORAVTANSINE

    AstraZeneca AB

    Advanced Platinum-resistant Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  15. DOXORUBICIN, EPIRUBICIN, CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., MITOMYCIN, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, IDARUBICIN

    Ningbo Cancer Hospital

    Intermediate stage Hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  16. DOXORUBICIN, Pralatrexate, PREDNISONE, Belinostat, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE

    Lacuna Pharma Pty Ltd

    Peripheral T-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. DS-8201a

    Daiichi Sankyo

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  18. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  19. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.

    Daiichi Sankyo

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  20. DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  22. DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  23. Dabrafenib

    Novartis Pharmaceuticals

    Malignant Melanoma

    phase 3 small molecule completed

    1 trial

  24. Dactinomycin

    Children's Hospital of Fudan University

    Adult Kidney Wilms Tumor

    phase 3 mab active

    1 trial

  25. Darbepoetin alfa

    Amgen

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  26. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  27. Darovasertib

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  28. Dato-DXd

    AstraZeneca

    Breast Cancer

    phase 3 small molecule active

    2 trials

  29. Datopotamab deruxtecan, DOCETAXEL

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  30. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  31. Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  32. Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  33. Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, Matching placebo tablets without active substance, Idarubicin Ebewe 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quizartinib, Citarabina Hikma 100mg/5mL Soluzione Iniettabile, Quizartinib

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  34. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  35. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  36. Decitabine plus HAAG regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  37. Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  38. Dendritic cell immunotherapy

    NORTHWEST BIOTHERAPEUTICS INC

    Prostate Cancer

    phase 3 small molecule terminated

    1 trial

  39. Denosumab

    Amgen

    Cancer

    phase 3 small molecule completed

    1 trial

  40. Dinutuximab

    United Therapeutics Europe Ltd

    Small Cell Lung Cancer

    phase 3 mab completed

    1 trial

  41. Distress Thermometer and Problems List

    United Therapeutics Europe Ltd

    Cancer

    phase 3 other completed

    1 trial

  42. Docetaxel

    AstraZeneca

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  43. Docetaxel

    Sanofi Pasteur

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  44. Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  45. Docetaxel+lobaplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma

    phase 3 small molecule active

    1 trial

  46. Docetaxel, cisplatin and fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  47. Dociparstat

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  48. Domvanalimab

    Arcus Biosciences

    Advanced Upper Gastrointestinal Tract Adenocarcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase III programs exist?

1,266 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.